Rx Analytic

Creating a nano-encapsulating pharmaceutical carrier and co-optimized inhaler, for precise and highly efficient transport of drug compounds into the lungs with in vivo control of pharmacokinetics.

Inhalation

A step beyond today’s inhalers for controlled local treatment of lung disease which avoids the dose-limiting side effects of systemic therapies. In-vivo control of the drug release kinetics makes local treatment possible by maintaining a therapeutic concentration over a programmed release period. It presents the opportunity to design protocols with both a rapid onset of action and a long duration of benefit. This cannot be done with any of today’s inhalers.

\

Delivery

RxA’s nano-encapsulating process is a payload independent carrier for pulmonary drug delivery. It enables efficient and precise transport to the site of underlying pathology. The platform stabilizes the therapeutic asset, generates incohesive particles, and controls release kinetics. It’s matched to a next-generation and co-optimized dry powder inhaler that meters a steady flow at modest inspiratory rates to generate a slow non-agglomerated plume throughout the patients breadth.

Scalability

The platform is scalable and underlying pathology is targeted by programming the time-to-maximum concentration and geometric particle size independently from aerodynamic diameter. These degrees of freedom are used to select: central and small airway epithelium, the small airway and alveolar spaces, peripheral lymph nodes, or cell cytosol in tumor tissues with the ability to time drug release to occur after non-internalized particles are cleared from ciliated epithelium.

Partnering & Innovation:

The pharmaceutical industry is expected to lose over $100 billion in revenue in the next several years from patent expiration. The cost of new drug development is very high, and the number of new drugs approved each year is low. Another issue is the very high cost of late-stage drug licensing deals. There is a growing need for earlier and lower cost agreements to bring transformational new technologies to the market that will improve the efficacy of drugs and the lives of patients. For these reasons, and the novelty and utility of our approach, we are seeking an early pharmaceutical research, collaboration, or licensing agreement. RxA’s pulmonary drug-delivery platform is a payload independent, scalable, efficient, and precise carrier technology that controls in vivo drug release kinetics to effectively treat lung disease without the dose-limiting side effects of systemic therapies.

Let’s connect:

We’re approachable and interested in your needs.

Ridgefield, CT 06877

203-733-0837
Connect@RxAnalytic.com

Contact us:

* Site under construction.